Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $1.3 billion.

  • Beam Therapeutics' Liabilities and Shareholders Equity rose 1192.74% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 39.68%. This contributed to the annual value of $1.1 billion for FY2024, which is 2438.08% down from last year.
  • As of Q3 2025, Beam Therapeutics' Liabilities and Shareholders Equity stood at $1.3 billion, which was up 1192.74% from $1.4 billion recorded in Q2 2025.
  • Over the past 5 years, Beam Therapeutics' Liabilities and Shareholders Equity peaked at $1.5 billion during Q4 2021, and registered a low of $693.2 million during Q1 2021.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $1.3 billion (2022), whereas its average is $1.3 billion.
  • Per our database at Business Quant, Beam Therapeutics' Liabilities and Shareholders Equity soared by 31561.88% in 2021 and then plummeted by 2438.08% in 2024.
  • Beam Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $1.5 billion in 2021, then decreased by 9.0% to $1.3 billion in 2022, then rose by 8.79% to $1.5 billion in 2023, then decreased by 24.38% to $1.1 billion in 2024, then grew by 18.78% to $1.3 billion in 2025.
  • Its Liabilities and Shareholders Equity was $1.3 billion in Q3 2025, compared to $1.4 billion in Q2 2025 and $1.5 billion in Q1 2025.